Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Comparing Medications for Adults With Type 2 Diabetes

Slide: 20 of 35

Details of the HbA1c and Weight Intermediate Outcomes: Monotherapy versus Two-Drug Combination Therapy

HbA1c
All combination therapies were better at reducing HbA1c than monotherapy regimens, with between-group differences of about 1 percent. The strength of evidence was rated high for metformin versus metformin plus thiazolidinediones, and metformin versus metformin plus sulfonylureas, and graded moderate for metformin versus metformin plus DPP-4 inhibitors.

Weight
Metformin monotherapy had a more favorable effect on weight compared with the combination of metformin plus a thiazolidinedione (between-group difference of -2.2 kg, 95 percent CI, -2.6 kg to -1.9 kg) or metformin plus a sulfonylurea (pooled between-group difference of -2.3 kg, 95 percent CI, -3.3 kg to -1.2 kg). The strength of evidence was graded high for these comparisons. Metformin monotherapy had no significant differences in weight when compared with the combination of metformin plus DPP-4 inhibitors (pooled between-group difference of -0.2 kg, 95 percent CI, -0.7 kg to 0.2 kg). The strength of evidence was graded moderate for this comparison.